The Georgian Health Ministry on Thursday said it would have a “strict response” to “artificially increased prices” on expensive oncological medicines, after the “significant” surge of prices by “some” pharmaceutical companies.
The oncological medications are financed by the state’s universal health care programme and the reference prices have not been established for them, the Ministry noted.
According to the National Health Agency’s data, the companies selling expensive oncological medicines have established identical prices for medicines, the state body emphasised, adding the pharmaceutical companies might have an “unfair agreement” between each other to “improperly” use the dominant position on the market, which “significantly harmed” the oncology patients and the state, financing their treatment.
The Ministry said the Georgian National Competition Agency was involved in studying possible "dishonest actions" on the part of individual pharmaceutical companies.
Within the Universal Healthcare Programme, ₾25,000 (about $9,710) is allocated annually per beneficiary for oncology treatment and as a result of artificially inflated prices, the patients’ access to medicines has been limited, the Ministry noted.